Johnson & Johnson Debt Conversion, Converted Instrument, Amount
Johnson & Johnson (JNJ) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2023-01-01, per its 10-K filed 2023-02-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-02-16
- Johnson & Johnson debt conversion, converted instrument, amount for fiscal 2023 was $0.00.
- Johnson & Johnson debt conversion, converted instrument, amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Johnson & Johnson debt conversion, converted instrument, amount for fiscal 2021 was $27.00M, a 2600.00% increase from fiscal 2019.
- Johnson & Johnson debt conversion, converted instrument, amount for fiscal 2019 was $1.00M, a 83.33% decline from fiscal 2018.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2023-01-01 | $0.00 10-K · filed 2023-02-16 |
| 2022-01-02 | $0.00 10-K · filed 2023-02-16 |
| 2021-01-03 | $27.00M 10-K · filed 2023-02-16 |
| 2019-12-29 | $1.00M 10-K · filed 2022-02-17 |
| 2018-12-30 | $6.00M 10-K · filed 2021-02-22 |
| 2017-12-31 | $16.00M 10-K · filed 2020-02-18 |
| 2017-01-01 | $35.00M 10-K · filed 2019-02-20 |
| 2016-01-03 | $16.00M 10-K · filed 2018-02-21 |
| 2014-12-28 | $17.00M 10-K · filed 2017-02-27 |
| 2013-12-29 | $22.00M 10-K · filed 2016-02-24 |
| 2012-12-30 | $0.00 10-K · filed 2015-02-24 |
| 2012-01-01 | $1.00M 10-K · filed 2014-02-21 |
| 2011-01-02 | $1.00M 10-K · filed 2013-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |